A Lovely Surprise
We love to hear from ASPREE participants. Your letters share thoughtful suggestions, compliments, comments and questions.
And then there are notes, like this one “Wishing you and yours a happy day.” returned with an ALSOP questionnaire, which simply brightens our day.
Thank you.
Bendigo’s postive and active ageing newsetter ‘Zoom’, features a story on ASPREE’s Lynn O’Neill and her incredible knitting skills this month. Lynn moved from Melbourne to Central Victoria in late 2010, a move she hasn’t regretted. Read her story from Issue 3 Spring 2012 here: There was a time when local nurse Lynn O’Neill’s dream…
Details
Congratulations to the hardworking Biobank team and to 5,000 wonderful ASPREE participants. Together, we’ve reached the half way mark on this very important, world first, Healthy Ageing Biobank study. Many Biobank participants will be familiar with the ASPREE BioBus, a specially fitted mobile laboratory that enables participants in regional and rural Victoria, NSW and Tasmania to participate…
Details
Over 150 people marked the 500th participant in the ACT to be enrolled in the healthy ageing study, ASPREE (ASPirin in Reducing Events in the Elderly) at a morning tea in Canberra today. ASPREE, the largest ever primary prevention aspirin study in Australians aged 70 and over, is investigating whether aspirin can delay or prevent the…
Details
We’d love you to follow our progress on @ASPREE_aus What is twitter? It’s an online service that allows people to send messages limited to 140 characters per entry. The summary-like messages are instant and sent to those who follow you. Millions of people around the world have a twitter account. While we will be tweeting about ASPREE events…
Details
Senior ASPREE investigator, Professor Mark Nelson says a recent paper that links taking NSAID (Non Steroidal Anti-inflammatory Drugs) to a decrease in the risk of developing skin cancer underscores the importance of the ASPREE study. “We welcome the findings of this study as the possibility of aspirin having cancer preventing properties is one of the rationales…
Details
Popular morning radio personalities Ross and John on Melbourne radio station 3AW, interviewed Prof Andrew Tonkin, ASPREE senior investigator and Head of Cardiovascular Research Unit, Monash University about aspirin and the ASPREE trial. Hear Andrew discuss the pros and cons of aspirin and what the ASPREE study is really about. Click here to listen (run time…
Details
Recently published research suggesting aspirin could be used to combat cancer only reinforces the need for more in depth analysis, one of the world’s foremost aspirin experts has said. Principal Investigator to ASPREE (ASPirin in Reducing Events in the Elderly) Professor John McNeil said the research, conducted by a team at the University of Oxford…
DetailsResearch findings by Rothwell et al, (two in ‘The Lancet’ and one in ‘The Lancet Oncology’) to hit the media today are suggesting that daily aspirin can be used to help prevent and possibly treat cancer. Professor John McNeil, Principal Investigator of the ASPREE study in Australia puts these papers in context: The new research…
Details
“Recent headlines that ‘a daily dose of aspirin may do more harm than good’ have been described by one of Australia’s foremost experts on the drug as crude, sensational and likely to cause undue concern among Australians….” Read Professor Mark Nelson’s full interview published in the Australian Ageing Agenda in response to a UK aspirin study published in the Archives of Internal Medicine, :
© 2015 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy